Form 4: Pliant Therapeutics Chief Medical Officer Sells Shares to Cover Tax Obligations

Pliant Therapeutics' Chief Medical Officer, Eric Lefebvre, sold 18,478 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Summary

• Eric Lefebvre, the Chief Medical Officer of Pliant Therapeutics, sold 18,478 shares of common stock on January 17, 2025.
• The sale was executed at a weighted average price of $11.2011 per share.
• The shares were sold to cover withholding tax liabilities associated with the vesting of previously granted restricted stock units.
• The sale was part of a larger group sale by employees of the Issuer to cover their tax obligations.
• Following the transaction, Lefebvre beneficially owns 194,574 shares of Pliant Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, not indicative of any positive or negative sentiment towards the company's performance.

Industry Context

This is a routine transaction for company insiders to manage their tax obligations related to equity compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• The sale price of $11.2011 is within the range of recent trading activity for PLRX stock.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is not expected to be significant.
• The transaction is a normal part of executive compensation and does not indicate any change in the company's outlook.

Key Dates

Keywords

Pliant Therapeutics, PLRX, insider trading, stock sale, Form 4, Eric Lefebvre, Chief Medical Officer, restricted stock units, tax liabilities